Get Retatrutide Online in Minnesota | OmniRx Health

Medical Weight Loss Treatment in Minnesota

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Minnesota

Minnesota's healthcare heritage runs deep—from the Mayo Clinic to the innovative health systems of the Twin Cities. OmniRx Health builds on this tradition by bringing expert telemedicine to every corner of the state. Whether you're a Minneapolis professional, a college student in Duluth, a farmer in the southern counties, or a cabin owner in the Boundary Waters, our telehealth platform delivers the quality care Minnesota is known for, directly to you.

Our providers are licensed by the Minnesota Board of Medical Practice to deliver telehealth across the Land of 10,000 Lakes.

Minnesota pharmacies in the Twin Cities, Rochester, Duluth, and throughout rural areas provide prescription services with reliable delivery.

Minnesota has comprehensive telehealth laws that support virtual care while maintaining high standards for patient safety and quality.

Minnesota mandates telehealth coverage parity, and the state's strong healthcare infrastructure supports virtual care access.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Minnesota?: Yes, Minnesota has progressive telehealth laws supporting virtual healthcare. Licensed providers can offer comprehensive services including consultations, prescriptions, and ongoing care management.
Can northern Minnesota residents access specialists via telehealth?: Telehealth is essential for northern Minnesota, where specialist access may require long drives to the Twin Cities or Duluth. Our platform brings expert care to your location.
Does Minnesota insurance cover telehealth?: Yes, Minnesota requires insurers to cover telehealth services at parity with in-person visits. Most commercial plans and Medical Assistance cover virtual consultations.